IS7816A - Fenýl setin píperdín efnasambönd til notkunar semPPAR hvatar. - Google Patents

Fenýl setin píperdín efnasambönd til notkunar semPPAR hvatar.

Info

Publication number
IS7816A
IS7816A IS7816A IS7816A IS7816A IS 7816 A IS7816 A IS 7816A IS 7816 A IS7816 A IS 7816A IS 7816 A IS7816 A IS 7816A IS 7816 A IS7816 A IS 7816A
Authority
IS
Iceland
Prior art keywords
ppar
catalysts
phenyl substituted
piperidine compounds
substituted piperidine
Prior art date
Application number
IS7816A
Other languages
English (en)
Inventor
William Bagley Scott
Andrew Brandt Thomas
Wayne Dugger Robert
Andrew Hada William
Myers Hayward Cheryl
Liu Zhengyu
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS7816A publication Critical patent/IS7816A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IS7816A 2002-11-26 2005-04-20 Fenýl setin píperdín efnasambönd til notkunar semPPAR hvatar. IS7816A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42950602P 2002-11-26 2002-11-26
PCT/IB2003/005235 WO2004048334A1 (en) 2002-11-26 2003-11-14 Phenyl substituted piperidine compounds for use as ppar activators

Publications (1)

Publication Number Publication Date
IS7816A true IS7816A (is) 2005-04-20

Family

ID=32393563

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7816A IS7816A (is) 2002-11-26 2005-04-20 Fenýl setin píperdín efnasambönd til notkunar semPPAR hvatar.

Country Status (33)

Country Link
US (2) US7199243B2 (is)
EP (1) EP1567493B1 (is)
JP (1) JP4029091B2 (is)
KR (2) KR100875318B1 (is)
CN (1) CN100439337C (is)
AR (1) AR042131A1 (is)
AT (1) ATE425966T1 (is)
AU (1) AU2003276596B8 (is)
BR (1) BR0316521A (is)
CA (1) CA2507465C (is)
CO (1) CO5570701A2 (is)
DE (1) DE60326752D1 (is)
DK (1) DK1567493T3 (is)
EA (1) EA008928B1 (is)
ES (1) ES2321509T3 (is)
GT (1) GT200300258A (is)
HR (1) HRP20050437A2 (is)
IS (1) IS7816A (is)
MA (1) MA27532A1 (is)
MX (1) MXPA05005583A (is)
NL (1) NL1024881C2 (is)
NO (1) NO20052921L (is)
NZ (1) NZ539546A (is)
PE (1) PE20040699A1 (is)
PL (1) PL378268A1 (is)
PT (1) PT1567493E (is)
SI (1) SI1567493T1 (is)
TN (1) TNSN05146A1 (is)
TW (1) TW200424172A (is)
UA (1) UA83202C2 (is)
UY (1) UY28097A1 (is)
WO (1) WO2004048334A1 (is)
ZA (1) ZA200503104B (is)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2160002A1 (fr) 2008-08-28 2010-03-03 Oberthur Technologies Procédé d'échange de données entre deux entités électroniques
EP2160001A1 (fr) 2008-08-28 2010-03-03 Oberthur Technologies Procédé d'échange de données entre deux entités électroniques
EP2363825A1 (fr) 2010-03-04 2011-09-07 Inside Secure Procédé pour conduire une transaction au moyen d'un dispositif NFC

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20050437A2 (en) * 2002-11-26 2005-10-31 Pfizer Products Inc. Phenyl substituted piperidine compounds for the use as ppar activators
WO2005115389A2 (en) * 2004-05-25 2005-12-08 Pfizer Products Inc. Specific ppar agonists for treating negative energy balance
JP2008500328A (ja) * 2004-05-25 2008-01-10 ファイザー・プロダクツ・インク 新規な使用
US7902367B2 (en) 2004-08-11 2011-03-08 Kyorin Pharmaceutical Co., Ltd. Cyclic amino benzoic acid derivative
ATE439347T1 (de) * 2004-11-23 2009-08-15 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure- derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
JPWO2006101108A1 (ja) * 2005-03-23 2008-09-04 杏林製薬株式会社 新規環状アミノフェニルアルカン酸誘導体
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
BRPI0615248A2 (pt) * 2005-08-26 2009-07-14 Shionogi & Co derivado tendo atividade agonista de ppar
US9173875B2 (en) * 2006-04-11 2015-11-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Treatment for nicotine-induced lung disease using peroxisome proliferator-activated receptor gamma agonists
CA2669060A1 (en) * 2006-12-01 2008-06-05 Actelion Pharmaceuticals Ltd Piperidine compounds
EP2178534A4 (en) * 2007-07-17 2011-03-30 Merck Sharp & Dohme SOLUBLE EPOXYHYDROLASE HEMMER, COMPOSITIONS WITH SUCH COMPOUNDS AND TREATMENT METHODS THEREWITH
BRPI0813426A2 (pt) 2007-07-19 2014-12-23 Lundbeck & Co As H Composto, composição farmacêutica, métodos para modular a atividade de um receptor p2x7, para tratar uma condição, para inibir a morte de células gangliônicas retinais, para promover perda de peso,e para determinar a presença ou ausência de receptor p2x7 em uma amostra, preparação farmacêutica acondicionada, uso de composto ou sal ou hidrato do mesmo.
TW201006816A (en) 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
UA107938C2 (en) 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
WO2011037793A1 (en) * 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Substituted aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
TWI513695B (zh) * 2009-10-27 2015-12-21 Merck Sharp & Dohme （１，１，１，３，３，３－六氟－２－羥基丙－２－基）苯基衍生物
JP2014513923A (ja) 2011-03-04 2014-06-19 ファイザー・インク Ｅｄｎ３様ペプチドおよびその使用
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
RU2615769C2 (ru) * 2015-07-29 2017-04-11 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования "Уфимский Государственный Университет Экономики И Сервиса" Средство для ингибирования фермента альфа-амилазы
US20220411372A1 (en) * 2019-09-20 2022-12-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small-molecule inhibitors for the b-catenin/b-cell lymphoma 9 protein-protein interaction
CN116162056A (zh) * 2021-11-24 2023-05-26 上海医药工业研究院 β-catenin/BCL9蛋白-蛋白相互作用的小分子抑制剂及其应用
WO2024022521A1 (zh) * 2022-07-28 2024-02-01 南通环聚泰生物科技有限公司 靶向BCL9/β-连环蛋白互相作用的小分子化合物
WO2024145931A1 (zh) * 2023-01-06 2024-07-11 上海医药工业研究院有限公司 β-catenin/BCL9蛋白蛋白相互作用的小分子抑制剂及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2025518A1 (is) 1969-06-05 1970-12-10
US4476311A (en) 1980-03-12 1984-10-09 The Purdue Frederick Company Analgesic 4-carboxy-pyrrolidin-2-one compound
EP0077607A1 (en) * 1981-09-17 1983-04-27 Beecham Group Plc N-substituted 3-aryl piperidines and derivatives thereof
EP0115607A1 (de) * 1983-01-04 1984-08-15 MERCK PATENT GmbH Tetrahydrocarbazolderivate
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
WO1993007141A1 (en) 1991-10-11 1993-04-15 Smithkline Beecham Corporation Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production
WO1993012086A1 (en) * 1991-12-11 1993-06-24 Ss Pharmaceutical Co., Ltd. Arylamide derivative
JPH05255089A (ja) * 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
JP3233991B2 (ja) * 1992-06-26 2001-12-04 株式会社ソフィア 遊技機
EP0607536B1 (en) 1992-12-08 2001-01-24 Ss Pharmaceutical Co., Ltd. Arylamide derivatives
WO1996002250A1 (en) 1994-07-20 1996-02-01 Acea Pharmaceuticals Inc. Haloperidol analogs and the use thereof
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
DE19614204A1 (de) 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JPH09312086A (ja) * 1996-05-22 1997-12-02 Matsushita Electric Ind Co Ltd 光ディスク再生システム、光ディスク再生方法および光ディスク
WO1998005331A2 (en) 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
IT1286497B1 (it) 1996-11-20 1998-07-15 Italfarmaco Sud Spa Difosfine di tipo misto eteroariliche-ariliche come leganti chirali, relativi complessi con metalli di transizione e impiego di detti
BR9813801A (pt) * 1997-12-19 2000-10-03 Merck & Co Inc Composto, composição farmacêutica, e, processos para o tratamento, controle, ou prevenção, em um mamìfero, de diabete mellitus, de hiperglicemia, de hiperlipidemia, de obesidade, de hipercolesterolemia, e, de hipertrigliceridemia.
PT952154E (pt) 1998-04-16 2004-12-31 Pfizer Prod Inc N-acil- e n-aroil-aralquilamidas
US6376494B1 (en) 1998-06-15 2002-04-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
HN1999000149A (es) 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
GB9822473D0 (en) 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
CA2324330A1 (en) 1999-11-08 2001-05-08 Ssp Co., Ltd. 4-hydroxy-4-phenylpiperidine derivatives and pharmaceuticals containing the same
US20020045613A1 (en) 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
WO2001085716A1 (en) 2000-05-11 2001-11-15 Kyowa Hakko Kogyo Co., Ltd 2-piperidone compounds for the treatment of cancer
WO2001090101A1 (en) 2000-05-22 2001-11-29 Aventis Pharmaceuticals Inc. Arylmethylamine derivatives for use as tryptase inhibitors
AU2001211337A1 (en) 2000-10-06 2002-04-15 Smithkline Beecham Plc Process for the preparation of aryl-piperidine carbinols and intermediates thereof
AU2001294240A1 (en) 2000-10-12 2002-04-22 Ssp Co., Ltd. 2,2-diphenylbutanamide derivatives and medicines containing the same
JP2002173426A (ja) 2000-12-05 2002-06-21 Ss Pharmaceut Co Ltd 血糖低下剤
JP2004523543A (ja) * 2001-02-15 2004-08-05 ニューロサーチ、アクティーゼルスカブ 神経栄養活性を有する化合物とドパミン活性を増加させる化合物の組み合わせ作用によるパーキンソン病の治療法
CA2438551A1 (en) * 2001-02-15 2002-08-22 Pfizer Products Inc. Ppar agonists
HRP20050437A2 (en) * 2002-11-26 2005-10-31 Pfizer Products Inc. Phenyl substituted piperidine compounds for the use as ppar activators

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2160002A1 (fr) 2008-08-28 2010-03-03 Oberthur Technologies Procédé d'échange de données entre deux entités électroniques
EP2160001A1 (fr) 2008-08-28 2010-03-03 Oberthur Technologies Procédé d'échange de données entre deux entités électroniques
EP2363825A1 (fr) 2010-03-04 2011-09-07 Inside Secure Procédé pour conduire une transaction au moyen d'un dispositif NFC

Also Published As

Publication number Publication date
MXPA05005583A (es) 2005-07-27
PL378268A1 (pl) 2006-03-20
AU2003276596B8 (en) 2009-03-05
NO20052921L (no) 2005-08-18
TW200424172A (en) 2004-11-16
BR0316521A (pt) 2005-10-04
PE20040699A1 (es) 2004-10-23
EP1567493B1 (en) 2009-03-18
EP1567493A1 (en) 2005-08-31
CO5570701A2 (es) 2005-10-31
ZA200503104B (en) 2006-12-27
NL1024881A1 (nl) 2004-05-27
PT1567493E (pt) 2009-04-09
ATE425966T1 (de) 2009-04-15
KR100875318B1 (ko) 2008-12-22
UY28097A1 (es) 2004-06-30
KR20050086794A (ko) 2005-08-30
SI1567493T1 (sl) 2009-06-30
EA008928B1 (ru) 2007-08-31
UA83202C2 (ru) 2008-06-25
HK1083502A1 (zh) 2006-07-07
NO20052921D0 (no) 2005-06-15
NZ539546A (en) 2007-11-30
AU2003276596A1 (en) 2004-06-18
ES2321509T3 (es) 2009-06-08
CA2507465A1 (en) 2004-06-10
CN100439337C (zh) 2008-12-03
JP4029091B2 (ja) 2008-01-09
HRP20050437A2 (en) 2005-10-31
JP2006509001A (ja) 2006-03-16
GT200300258A (es) 2004-11-30
DE60326752D1 (de) 2009-04-30
TNSN05146A1 (fr) 2007-05-14
NL1024881C2 (nl) 2009-09-16
US20070191429A1 (en) 2007-08-16
CA2507465C (en) 2009-04-28
DK1567493T3 (da) 2009-06-08
MA27532A1 (fr) 2005-09-01
CN1717389A (zh) 2006-01-04
KR100760055B1 (ko) 2007-09-18
WO2004048334A1 (en) 2004-06-10
EA200500629A1 (ru) 2005-12-29
US20040157885A1 (en) 2004-08-12
AU2003276596B2 (en) 2009-02-12
AR042131A1 (es) 2005-06-08
KR20070063051A (ko) 2007-06-18
US7199243B2 (en) 2007-04-03

Similar Documents

Publication Publication Date Title
IS7816A (is) Fenýl setin píperdín efnasambönd til notkunar semPPAR hvatar.
ATE525377T1 (de) Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase
NO20054005D0 (no) Nye arylpiperazinylforbindelser
SE0301569D0 (sv) Novel compounds
NO20052928D0 (no) Nye kjemiske forbindelser
DK1677623T3 (da) Tyggeemne til kæledyr
ATE477257T1 (de) Piperidinylamino-thienoä2,3-dü- pyrimidinverbindungen
IS8228A (is) Ný asetídínefnasambönd
NO20052884D0 (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
NL1028192A1 (nl) Gesubstitueerde chinolineverbindingen.
IS8292A (is) Ný efnasambönd
DE60305332D1 (de) IMIDAZOi1,2-AöPYRIDINE
IS7585A (is) Ný piperadín efnasambönd
IS7827A (is) Ný efnasambönd
DK1556377T3 (da) Cyclopropylthienylcarboxamider som fungicider
NO20053753D0 (no) Karboksylsyreforbindelser.
NO20051500D0 (no) Substituerte heterocyklylpyrimidiner.
NO20055750D0 (no) Nye kjemiske forbindelser
NL1030010A1 (nl) 4-Amino-gesubstitueerde-2-gesubstitueerde-1,2,3,4- tetrahydrochinolineverbindingen.
ATE394370T1 (de) Von vitamin d abgeleitete monohalogenvinylverbindungen
ATE420079T1 (de) Substituierte aralkyl verbindungen
SE0203348D0 (sv) Novel compounds
SE0200523D0 (sv) New compounds
SE0203751D0 (sv) New Compounds
SE0201925D0 (sv) New compounds